Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa trial of M2951 in rheumatoid arthritis patients on stable methotrexate
2016-000064-42Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing M2951 + methotrexate with Placebo + methotrexate (2 arms). Primary endpoint: ACR20 response rate at Day 85. Started May 2016; status: completed.
02
Drugs
evobrutinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2016-000064-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000064-42.